Acute myeloid leukemia

Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome

Jorge E. Cortes1 · Florian H. Heide1,14 · Andrzej Hellmann3 · Walter Fiedler4 · B. Douglas Smith5 · Tadeusz Robak6 · Pau Montesinos7,8 · Daniel A. Pollyea9 · Pierre DesJardins10 · Oliver Ottmann11 · Weidong Wendy Ma12 · M. Naveed Shaik12 · A. Douglas Laird12 · Mirjana Zeremski12 · Ashleigh O’Connell12 · Geoffrey Chan12 · Michael Heuser13

Received: 11 October 2018 / Accepted: 2 November 2018 / Published online: 16 December 2018 © The Author(s) 2018. This article is published with open access

Abstract
Glasdegib is a Hedgehog pathway inhibitor. This phase II, randomized, open-label, multicenter study (ClinicalTrials.gov, NCT01546038) evaluated the efficacy of glasdegib plus low-dose cytarabine (LDAC) in patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome unsuitable for intensive chemotherapy. Glasdegib 100 mg (oral, QD) was administered continuously in 28-day cycles; LDAC 20 mg (subcutaneous, BID) was administered for 10 per 28 days. Patients (stratified by cytogenetic risk) were randomized (2:1) to receive glasdegib/LDAC or LDAC. The primary endpoint was overall survival. Eighty-eight and 44 patients were randomized to glasdegib/LDAC and LDAC, respectively. Median (80% confidence interval [CI]) overall survival was 8.8 (6.9–9.9) months with glasdegib/LDAC and 4.9 (3.5–6.0) months with LDAC (hazard ratio, 0.51; 80% CI, 0.39–0.67, P = 0.0004). Fifteen (17.0%) and 1 (2.3%) patients in the glasdegib/LDAC and LDAC arms, respectively, achieved complete remission (P < 0.05). Nonhematologic grade 3/4 all-causality adverse events included pneumonia (16.7%) and fatigue (14.3%) with glasdegib/LDAC and pneumonia (14.6%) with LDAC. Clinical efficacy was evident across patients with diverse mutational profiles. Glasdegib plus LDAC has a favorable benefit–risk profile and may be a promising option for AML patients unsuitable for intensive chemotherapy.

Introduction

Myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) are clinically and genetically heterogeneous myeloid stem cell disorders with a median age at onset of about 67 years [1].

Jorge E. Cortes jcortes@mdanderson.org

1 Department of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, TX, USA
2 Otto-von-Guericke University Medical Center, Magdeburg, Germany
3 Department of Haematology and Transplantology, Medical University of Gdansk, Gdansk, Poland
4 Department of Hematology and Oncology, University Hospital Hamburg-Eppendorf, Hamburg, Germany
5 Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA
6 Department of Hematology, Medical University of Lodz, Lodz, Poland
7 Hospital Universitari i Politècnic La Fe, Valencia, Spain
8 CIBERONC, Instituto Carlos III, Madrid, Spain
9 Division of Hematology, University of Colorado School of Medicine, Aurora, CO, USA
10 Hôpital Charles LeMoyne, Greenfield Park, QC, Canada
11 Division of Cancer and Genetics, School of Medicine, Cardiff University, Cardiff, UK
12 Pfizer Oncology, New York, NY, USA
13 Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
14 Present address: Internal Medicine II, University Hospital Jena, Jena, Germany
Older patients with AML or high-risk MDS have few treatment options and are often not eligible for intensive chemotherapy due to comorbidities and a higher incidence of high-risk biological features, which often lead to chemotherapy resistance.

This population is thus treated with less-aggressive therapies, including low-dose cytarabine (LDAC) and hypomethylating agents. However, studies with LDAC have demonstrated low response rates (7–18%), with median overall survival (OS) of 5 months in older patients [2–7]. With the hypomethylating agent decitabine, the response rate (18%) and median OS (7.7 months) were only slightly improved [5]. Therefore, novel therapeutic strategies are needed to achieve higher response rates, more durable responses, and improved survival in this hard-to-treat population.

The Hedgehog signaling pathway plays a key role in embryonic development and is typically silenced in adults [8]. Aberrant Hedgehog signaling has been implicated in hematologic malignancies and is critical for leukemia stem-cell survival and expansion [9–11]. Overexpression of Hedgehog pathway components was observed in chemotherapy-resistant myeloid leukemia cells, and pharmacologic inhibition of the Hedgehog pathway substantially enhanced the sensitivity to chemotherapy [12]. These findings provide the rationale for combining an inhibitor of Hedgehog pathway with chemotherapy.

Glasdegib is a potent and selective oral inhibitor of Hedgehog signaling through binding to Smoothened. In preclinical studies, glasdegib produced rapid and complete tumor regression as a single agent or in combination with chemotherapy, reduced expression of key leukemia stem-cell regulators, and decreased leukemia stem-cell populations in patient-derived AML cells [13, 14]. Glasdegib monotherapy demonstrated preliminary clinical activity in phase I trials in patients with hematologic malignancies [15, 16]. Therefore, glasdegib plus chemotherapy represents a mechanistically attractive treatment approach for patients with AML or MDS.

A phase Ib/II, open-label, international, multicenter study evaluated safety and efficacy of glasdegib plus intensive chemotherapy (cytarabine and daunorubicin), LDAC, or decitabine in previously untreated patients with AML or high-risk MDS [17, 18]. Here we describe results from the ongoing phase II, randomized, open-label portion of the study that assessed the efficacy and safety of glasdegib plus LDAC (glasdegib/LDAC) versus LDAC in patients with AML or high-risk MDS who were not eligible for intensive chemotherapy.

Methods

Patients

Eligible patients were aged ≥55 years with newly diagnosed, previously untreated AML or high-risk MDS according to the World Health Organization (WHO) 2008 Classification [19]. For a diagnosis of high-risk MDS RAEB-2 (refractory anemia with excess blasts 2), the patient must have 10–19% bone marrow blasts. Patients had to have a known cytogenetic profile at study entry and considered not suitable for intensive chemotherapy, defined by ≥1 of the following criteria [20]: age ≥75 years; serum creatinine >1.3 mg/dL, severe cardiac disease (e.g., left ventricular ejection fraction <45% by multi-gated acquisition or echocardiography at screening), or Eastern Cooperative Oncology Group Performance Status (ECOG PS) = 2. Patients with ECOG PS = 0 or 1 who met ≥1 other inclusion criteria listed above were also eligible (for full inclusion criteria, see Supplementary materials). Patients were excluded if they had acute promyelocytic leukemia, t(9;22) cytogenetic translocation, active other malignancy, known active uncontrolled leukemia of the central nervous system, or prior treatment with Hedgehog inhibitor or other investigational agent for the treatment of an antecedent hematologic disease (for more details, see Supplementary materials).

Study design and treatment

In this open-label, multicenter phase II study (ClinicalTrials.gov, NCT01546038) carried out in Europe and North America, patients were stratified by cytogenetic risk factor (good/intermediate or poor) and randomized (2:1) to receive glasdegib/LDAC or LDAC. The primary objective was OS. Secondary objectives included clinical efficacy endpoints, safety and tolerability, pharmacokinetics (PK), pharmacodynamics, and effect on corrected QT (QTc) interval.

Patients were classified as having poor-risk disease if they had one of the following cytogenetic features: inv(3), t(6;9), 11q23, –5, –5q, –7, abnormal (17p), or complex karyotype (≥3 clonal abnormalities). Patients with none of these features were classified as having good/intermediate-risk disease [21, 22]. Glasdegib 100 mg once daily was administered orally in 28-day cycles on a continuous basis and LDAC 20 mg was administered subcutaneously twice daily for 10 days every 28 days. Patients remained on treatment until disease progression, unacceptable toxicity, or patient refusal. All patients were followed up for post-treatment survival status for 4 years from randomization.

Patient randomization was obtained by the investigator or the designee from the interactive voice response system. Masking was not applicable for this open-label study.

This study was conducted in compliance with the Declaration of Helsinki, the International Council for Harmonisation Good Clinical Practice Guideline, and local regulatory requirements. The final protocol, amendments, and informed consent documents were approved by
institutional review board or independent ethics committee at each investigational center. All patients provided informed consent.

**Assessments**

**Efficacy**

Response to treatment was assessed based on the International Working Group response criteria and WHO Guidelines for MDS and AML. Immunophenotyping and cytogenetics were performed for all bone marrow samples (Supplementary materials).

**Pharmacokinetics**

Blood samples for PK analysis of glasdegib were analyzed for concentrations of glasdegib at Covance Bioanalytical Services, LLC (Indianapolis, IN, USA) using a validated, sensitive, and specific high-performance liquid chromatography–tandem mass spectrometric approach (Supplementary materials).

**Safety**

Safety assessments included adverse events (AEs), classified and graded based on the National Cancer Institute Common Terminology Criteria for Adverse Events v4.0, laboratory evaluations, vital signs, physical examinations, and 12-lead electrocardiograms. Treatment duration and time of treatment exposure of glasdegib were also calculated (Supplementary materials).

**Biomarker analyses**

Biomarker assessments included mutational status of the following genes: CEBPA, DNMT3A, FLT3, IDH1, IDH2, KIT, KRA5, NPM1, NRAS, RUNX1, TET2, and WT1. Whole blood samples from serial blood draws were analyzed for gene expression using TaqMan Low-Density Microarrays, including 21 target genes implicated in Hedgehog pathway signaling and/or AML pathobiology (Supplementary materials).

**Statistical analyses**

OS was defined as time from the date of randomization to death from any cause. Patients not known to have died at the last follow-up were censored on the date they were last known to be alive. The reported median OS for LDAC was approximately 5 months [2–4] and the expected median OS for glasdegib/LDAC was 8 months, resulting in an expected hazard ratio (HR) = 0.625 (i.e., 60% improvement in OS). A total of 132 patients would be randomized at 2:1 ratio (i.e., 88 in the glasdegib/LDAC arm and 44 in the LDAC alone arm), of which 92 OS events observed would provide 80% power to detect the 60% improvement in OS at one-sided significance level of 0.10 with an interim analysis (IA) for futility. The IA would occur when 46 OS events were observed (i.e., 50% information). Since the IA was for futility only, no alpha would be spent at the IA. The rh(1) spending function was used as the beta-spending function for futility at the IA. If exactly 46 OS events were observed at the IA, the futility boundary would be crossed if the observed HR > 0.92. The futility boundary would be calculated accordingly using the chosen spending function and number of OS events actually observed at the IA.

Median OS and 80% confidence interval (CI) were analyzed using the Kaplan–Meier method. A stratified log-rank test (one-sided α = 10%) was used to compare OS between the treatment arms. A Cox proportional hazard regression stratified by prognosis (good/intermediate versus poor) was used to estimate the HR and 80% CI of OS. Other efficacy endpoints were summarized descriptively and included complete remission (CR) and CR with incomplete blood count recovery (CRi). An additional efficacy endpoint for AML included morphologic leukemia-free state (MLFS). Additional efficacy endpoints for MDS included marrow CR (mCR) and partial remission. Safety data were summarized descriptively and included all randomized patients who received at least one dose of any of the study medications.

**Results**

**Patients**

Overall, 132 patients were randomized to receive glasdegib/LDAC (n = 88) and LDAC (n = 44); among them, 84 and 41 patients received study treatments, respectively (Fig. 1). Patient demographic and baseline characteristics are summarized in Table 1. More male patients were included (69 in the glasdegib/LDAC and 26 in the LDAC group) and over half of the patients in each group (53/88 [60.2%] in the glasdegib/LDAC and 24/44 [54.5%] in the LDAC group) were aged >75 years. The median (range) number of cycles administered was 3 (1–35) with glasdegib/LDAC and 2 (1–9) with LDAC. Among patients who received treatment, 37/84 (44%) patients in the glasdegib/LDAC group and 15/41 (36.6%) patients in the LDAC group received follow-up systemic therapies after discontinuation of the study treatment. The majority of patients (34/84 [40.5%] in the glasdegib/LDAC and 14/41 [34.1%] in the LDAC group) received chemotherapy, primarily hypomethylating agents or palliative chemotherapy (Table S1).
Median follow-up for OS was 21.7 months with glasdegib/LDAC and 20.1 months with LDAC. The corresponding number of deaths were 68/88 (77.3%) and 41/44 (93.2%) patients. The main cause of death in both arms was disease progression (Tables S2 and S3). This translated into a median (80% CI) OS of 8.8 (6.9–9.9) months with glasdegib/LDAC and 4.9 (3.5–6.0) months with LDAC (HR, 0.51 [80% CI, 0.39–0.67], P = 0.0004) (Fig. 2). The probability (80% CI) of being alive at 6 and 12 months, respectively, was 59.8% (52.6–66.3) and 39.5% (32.6–46.3) with glasdegib/LDAC versus 38.2% (28.6–47.7) and 9.5% (4.8–16.3) with LDAC. Results were similar when separate Cox proportional hazards model were estimated by cytogenetic risk (Fig. 3). In patients with AML (n = 116), median (80% CI) OS was 8.3 (6.6–9.5) months with glasdegib/LDAC and 4.3 (2.9–4.9) months with LDAC (HR, 0.46 [80% CI, 0.35–0.62], P = 0.0002). In patients with MDS (n = 16), median (80% CI) OS was 10.9 (1.6–12.5) months with glasdegib/LDAC and 10.3 (6.0–11.7) months with LDAC (HR, 0.77 [80% CI, 0.37–1.63], P = 0.3280).

Fifteen of 88 (17.0%) patients in the glasdegib/LDAC arm and 1/44 (2.3%) patient in the LDAC arm achieved CR (P < 0.05, Table 2). In the glasdegib/LDAC arm, median (range) duration of response was 9.9 (0.03–28.8) months for patients with CR and 6.5 (0.03–28.8) months for patients with either CR, CRi, or MLFS. In the AML population, overall response rate (ORR; defined as CR plus CRi plus MLFS) was 26.9% (21/78) with glasdegib/LDAC and 5.3% (2/38) with LDAC. In the MDS population, ORR (defined as CR plus mCR) was 20.0% (2/10) with glasdegib/LDAC and 5.3% (2/38) with LDAC.
and 0% (0/6) with LDAC. Best overall response with other responses of interest for patients with AML and MDS are summarized in Tables S4 to S6.

**Pharmacokinetics**

Eighty-three and 69 patients in the glasdegib/LDAC arm were analyzed for PK concentration and PK parameters, respectively. Sixty-one of 69 patients evaluable for PK parameters were analyzed on Cycle 1 Day 10; of these, 41 did not receive cytochrome P450 (CYP) 3A4 (CYP3A4) inhibitors concomitantly. Since CYP3A4 inhibitors have the potential to increase glasdegib plasma exposure, this group was considered to more accurately represent glasdegib plasma PK parameters for the 100-mg once-daily dose. These patients showed a somewhat lower exposure to glasdegib than those with exposure to CYP3A4 inhibitors.

### Table 1 Patient demographic and baseline characteristics

|                         | Glasdegib 100 mg +LDAC, N = 88 | LDAC, N = 44 |
|-------------------------|--------------------------------|-------------|
| **Sex, n (%)**          |                                |             |
| Female                  | 19 (21.6)                      | 18 (40.9)   |
| Male                    | 69 (78.4)                      | 26 (59.1)   |
| **Age (years), n (%)**  |                                |             |
| 55–64                   | 2 (2.3)                        | 1 (2.3)     |
| 65–74                   | 33 (37.5)                      | 19 (43.2)   |
| ≥75                     | 53 (60.2)                      | 24 (54.5)   |
| **Mean (SD)**           | 76.2 (6.2)                     | 74.5 (4.9)  |
| **Median (range)**      | 77 (63–92)                     | 75 (58–83)  |
| **Race, n (%)**         |                                |             |
| White                   | 85 (96.6)                      | 44 (100.0)  |
| Black                   | 1 (1.1)                        | 0           |
| Asian                   | 2 (2.3)                        | 0           |
| **Body mass index (kg/m²)** |                            |             |
| Mean (SD)               | 27.4 (4.2)                     | 28.2 (5.5)  |
| Range                   | 17.5–41.9                      | 20.0–48.2   |
| **Peripheral blood white cell count (10³/mm³)** |                        |             |
| Median (range)          | 2.3 (0.6–64.0)                 | 3.6 (1.1–45.2) |
| **Diagnosis, n (%)**    |                                |             |
| AML                     | 78 (88.6)                      | 38 (86.4)   |
| MDS                     | 10 (11.4)                      | 6 (13.6)    |
| **Bone marrow blasts (%)** |                                 |             |
| With AML, median (range) | 41.0 (16.0–100.0)              | 46.0 (13.0–95.0) |
| With MDS, median (range) | 14.0 (7.5–18.0)               | 16.0 (10.5–19.0) |
| **Duration since histopathological diagnosis (months)** |              |             |
| AML, median (range)     | 0.6 (0.03–3.52)                | 0.5 (0.07–3.84) |
| MDS, median (range)     | 1.0 (0.20–13.63)               | 2.2 (0.43–14.98) |
| **ECOG performance status, n (%)** |                               |             |
| 0                       | 11 (12.5)                      | 3 (6.8)     |
| 1                       | 29 (33.0)                      | 18 (40.9)   |
| 2                       | 47 (53.4)                      | 23 (52.3)   |
| Not reported            | 1 (1.1)                        | 0           |
| **Cytogenetic risk, n (%)** |                                 |             |
| Good/intermediate risk   | 52 (59.1)                      | 25 (56.8)   |
| Poor risk               | 36 (40.9)                      | 19 (43.2)   |
| **ELN risk stratification for AML [21], n (%)** |                              |             |
| Favorable               | 5 (6.4)                        | 3 (7.9)     |
| Intermediate-I          | 27 (34.6)                      | 11 (28.9)   |
| Intermediate-II         | 21 (26.9)                      | 8 (21.1)    |
| Adverse                 | 25 (32.1)                      | 16 (42.1)   |

**Table 1 (continued)**

|                         | Glasdegib 100 mg +LDAC, N = 88 | LDAC, N = 44 |
|-------------------------|--------------------------------|-------------|
| **Prognostic factors for MDS, n (%)** |                             |             |
| Good                     | 3 (30.0)                       | 2 (33.3)    |
| Intermediate             | 1 (10.0)                       | 3 (50.0)    |
| Poor                     | 6 (60.0)                       | 1 (16.7)    |
| **MDS IPSS score [22], n (%)** |                             |             |
| 0.5–1 (Intermediate-1)   | 0                              | 2 (33.3)    |
| 1.5–2 (Intermediate-2)   | 4 (40.0)                       | 4 (66.7)    |
| ≥2.5 (High)             | 6 (60.0)                       | 0           |
| **Prior therapy with MDS drug, n (%)** |                             |             |
| Azacitidine              | 13 (14.8)                      | 8 (18.2)    |
| Decitabine               | 2 (2.3)                        | 1 (2.3)     |

AHD antecedent hematologic disease, AML acute myeloid leukemia, CR complete remission or complete response, ECOG Eastern Cooperative Oncology Group, HMA hypomethylating agents, IPSS International Prognostic Scoring System, LDAC low-dose cytarabine, MDS myelodysplastic syndrome, SD standard deviation

aSecondary AML included AML evolving from MDS or other AHD and AML after previous cytotoxic therapy or radiation. Secondary MDS included MDS from prior AHD

bFor AML, good/intermediate cytogenetic risk = favorable, intermediate-I, and intermediate-II risk groups; poor cytogenetic risk = adverse risk group
cMDS risk was assessed by cytogenetic abnormalities that were known at the time the study was initiated; good/intermediate cytogenetic risk = good and intermediate risk groups; poor cytogenetic risk = poor risk group
dAll patients who received prior HMA therapy were considered refractory and 0% (0/6) with LDAC. Best overall response with other responses of interest for patients with AML and MDS are summarized in Tables S4 to S6.
Summary of glasdegib PK parameters for glasdegib/LDAC arm on Cycle 1 Day 10 is presented in Table S7. Median glasdegib plasma concentration–time profile on Cycle 1 Day 10 is presented in Fig. S1.

Safety

The median (range) treatment duration was 2.7 (0.1–31.9) months with glasdegib/LDAC and 1.5 (0.2–7.9) months with LDAC. The mean relative dose intensity (for calculations, see Supplementary materials) of glasdegib was 89.0% for the glasdegib/LDAC arm, and the mean relative LDAC dose intensity was 95.5% for the glasdegib/LDAC arm and 96.1% for the LDAC arm, respectively.

The most frequently (>5% of patients) reported non-hematologic grade 3/4 all-causality AEs with glasdegib/LDAC were pneumonia (16.7% [14/84]), fatigue (14.3% [12/84]), dyspnea (7.1% [6/84]), hyponatremia, sepsis, and syncope (6.0% [5/84], each), and pneumonia (14.6% [6/41]) with LDAC (Table 3). The most frequently (>5% of patients) reported nonhematologic grade 3/4 treatment-related AE (i.e., related to either LDAC and/or glasdegib) was fatigue (10.7% [9/84]), which occurred in the glasdegib/LDAC arm (Table S8).

Thirty of 84 (35.7%) and 19/41 (46.3%) patients permanently discontinued study treatments due to AEs, with 9/84 (10.7%) and 3/41 (7.3%) patients discontinuing due to treatment-related (per investigator’s assessment) AEs in the glasdegib/LDAC and LDAC arms, respectively. In the glasdegib/LDAC arm, 47/84 (56.0%) patients temporarily discontinued glasdegib and/or LDAC and 22/84 (26.2%) patients had study treatment dose reduced owing to AEs. In the LDAC arm, 13/41 (31.7%) patients temporarily discontinued LDAC due to AEs. No dose reduction in LDAC due to AEs was reported.

Serious AEs were reported in 66/84 (78.6%) patients in the glasdegib/LDAC arm and 32/41 (78.0%) patients in the LDAC arm. The most frequently (≥15% of patients) reported serious AEs were febrile neutropenia (28.6% [24/84] with glasdegib/LDAC, 17.1% [7/41] with LDAC) and pneumonia (22.6% [19/84] and 17.1% [7/41], respectively). In the glasdegib/LDAC arm, 3/84 (3.6%) patients had serious acute kidney injury (1 considered related to glasdegib) and 1/84 (1.2%) patient had serious muscle spasms (considered related to glasdegib).

Nine and five patients in the glasdegib/LDAC and LDAC arms, respectively, had elevated liver function parameters (total bilirubin, aspartate aminotransferase, and/or alanine aminotransferase). Most were grade 1/2; 3 patients in the glasdegib/LDAC arm had grade 3 (1 related and 2 unrelated to treatment). No patient had concurrent elevations of all enzymes and none was confirmed as Hy’s law case [25]. No elevated liver enzymes led to permanent discontinuations of study treatments.

Abnormal Frederica’s QTc (QTcF) findings, either mean QTcF >480 ms and/or mean QTcF increase >60 ms from baseline, occurred in 9 patients treated with glasdegib/LDAC and 5 treated with LDAC. QTcF prolongation >500 ms was less frequent with glasdegib/LDAC versus LDAC (6.0% [5/83] versus 11.8% [2/17]). Two
patients temporarily discontinued treatment due to glasdegib-related electrocardiogram QT prolongation. Two patients had permanent dose reduction due to treatment-related electrocardiogram QT prolongation, 1 of which was related to glasdegib. No patients had Torsades de Pointes.

Biomarker analyses

Eighty-eight patients were included in baseline mutational analyses of bone marrow and/or peripheral blood, including 61 patients who received glasdegib/LDAC and 27 patients who received LDAC. No significant differences in mutational

Fig. 3 Kaplan-Meier estimate of overall survival, full analysis set, in patients at A good/intermediate cytogenetic risk and B poor cytogenetic risk. CI confidence interval, HR hazard ratio, LDAC low-dose cytarabine, OS overall survival
Patients with CR, 80% CI \(a\) 11.9

Cytogenetic risk

| CR, n | 80% exact CI \(b\) | Poor cytogenetic risk |
|-------|------------------|----------------------|
| 52    | 12.3–28.1        | 36                   |
| 25    | 0.0–8.8          | 19                   |

Combination versus LDAC

| Pearson Chi-square test for all enrolled patients (unstratified) | CMH test for all enrolled patients stratified by cytogenetics\(c\) |
|------------------------------------------------------------------|------------------------------------------------------------------|
| P value                                                         | Odds ratio (80% CI)                                               |
| 0.0142                                                          | 5.03 (1.59–15.88)                                                |

CI confidence interval, CMH Cochran–Mantel–Haenszel, CR complete remission, IVRS interactive voice response system, LDAC low-dose cytarabine

\(a\) Using normal approximation

\(b\) Using exact method based on binomial distribution

\(c\) Good/intermediate and poor cytogenetic risk based on IVRS

frequency between responding and non-responding patients were evident (Fisher’s exact test, \(P > 0.05\) for each of the 12 genes analyzed). Responses were observed in patients bearing mutations in \(≥ 1\) of all 12 genes assessed except K\textsubscript{RAS}, but the small numbers preclude firm conclusions of associations of mutations in specific genes with response to therapy (Table S9). However, nonsignificant trends suggest that gene mutations associated with a favorable overall response to the combination treatment include CEBPA, IDH1, NPM1, RUNX1, and TET2, whereas gene mutations associated with an unfavorable overall response to the combination treatment include DNMT3A, IDH2, and NRAS/\textsubscript{KRA}. Further, an ad hoc exploratory analysis demonstrated no significant relationship to response for TP\textsubscript{53} mutational status (data not shown). Findings of RNA biomarker analysis are described in Supplementary materials.

**Discussion**

This randomized phase II trial in patients with AML or high-risk MDS met its primary endpoint, as the addition of glasdegib to LDAC demonstrated statistically significant and clinically meaningful OS improvement. The patients treated with glasdegib/LDAC achieved a 49% reduction in the risk of death relative to LDAC (median 8.8 versus 4.9 months; HR, 0.51 [80% CI, 0.39 to 0.67], \(P = 0.0004\)). In terms of the HR, improvement in OS was consistent across pre-specified subgroups by cytogenetic risk, particularly in patients with good/intermediate cytogenetic risk. Furthermore, ORR with glasdegib/LDAC (26.9%) was higher compared with LDAC (5.3%). These results, together with the manageable safety profile, make the combination of Hedgehog inhibition with LDAC a compelling therapeutic approach particularly for patients with AML ineligible for intensive chemotherapy.

The subset of MDS patients treated with glasdegib/LDAC achieved a 22.8% reduction in the risk of death relative to LDAC, though the 80% CI around the OS HR encompassed one and the sample size was small. Considering that the analysis of patients with MDS was limited by the small sample size, more patients with MDS are being assessed (ClinicalTrials.gov, NCT02367456) to better understand the impact of glasdegib in MDS.

A median of two cycles of LDAC was administered, which was a shorter treatment period than the four cycles delivered in a prior study [26]. The open-label design of the current study may have contributed to this short treatment period with LDAC; however, this median number of cycles of LDAC was consistent with a most recent report by Dennis et al. [27]. The CR rate in patients treated with glasdegib/LDAC (17.0%) was higher than in those treated with LDAC (2.3%). These results showed a lower CR rate with LDAC than previously published (7–22%), potentially because of the short treatment period (1.5 months) with LDAC in the current study [2, 5–7, 26, 28, 29]. The low CR rate in the LDAC arm in the current study may also be due in part to the high proportion of patients with secondary AML who are known to be resistant to chemotherapy [30]. However, median OS with LDAC was similar to that observed in previous studies, suggesting that the control arm is representative of clinical expectations with this regimen [6, 31, 32].

In the population treated with glasdegib/LDAC, glasdegib mean steady-state plasma PK parameters at 100 mg once daily were in agreement with the mean parameters observed in the phase Ib portion (Arm A) of the study [17]. The maximum plasma concentration (\(C_{\text{max}}\)) of glasdegib at 100 mg is adequate to cover the half maximal inhibitory concentration values required for inhibition of the Hedgehog pathway in vitro [16]. The similar means of \(C_{\text{max}}\) and \(AUC_{\text{tau}}\) and the variability in these parameters (range, 44–61%) suggest that the intermittent use of moderate or strong CYP3A4 inhibitors is not associated with a large increase in glasdegib exposures on Cycle 1 Day 10. This indicates that...
CYP3A4 inhibitors may be used concomitantly as medically necessary.

Although comparison between trials should be considered with caution due to potential methodologic and other differences, median OS with glasdegib/LDAC compared favorably to previously reported outcomes with the combinations of LDAC/imatinib (4.6 months), LDAC/lin-tuzumab (4.7 months), or LDAC/volasertib (phase II 8.0 months, phase III 4.8 months) [6, 31–33]. Importantly, the addition of glasdegib to LDAC was generally well tolerated, with a manageable safety profile consistent with elderly patients receiving chemotherapy and toxicities reported for other marketed Smoothened inhibitors. The frequencies of alopecia, muscle spasms, and dysgeusia were numerically lower than what has been previously reported for Smoothened inhibitors [34–36]. The most common AEs occurring at higher rates in the glasdegib/LDAC versus LDAC arm were cytopenias and gastrointestinal events (mostly grade 1–2). Cytopenias were not accompanied by increases in sepsis or bleeding as compared with LDAC. Patients in the glasdegib/LDAC arm remained longer on treatment compared with the LDAC arm; therefore, it is possible the higher incidence of cytopenias in the glasdegib/LDAC arm was due to the longer duration of chemotherapy.

Preliminary signs of clinical efficacy were evident across patients with diverse mutational profiles, suggesting the potential for broad efficacy of glasdegib in combination with LDAC. However, no significant correlations were evident between mutational status of any of the individual 12 reported genes and clinical response. Nonsignificant trends suggesting association of gene mutations with response or lack of response were noted, but further research is required.

Reducing the incidence of disease progression to prolong survival remains the highest unmet medical need in the treatment of AML. Various agents targeting distinct pathways or markers are currently in development or have become available for clinical management of AML, such as azacitidine and venetoclax. Both drugs showed promising effects in treating AML as debulking agents [37, 38] via a different mechanism than that of the stem cell agent glasdegib. Preclinical data showed synergistic activity of Smoothened inhibitor (erismodegib) and azacitidine [39], and in a phase I trial glasdegib plus azacitidine showed evidence of clinical activity with no evidence of drug–drug interaction [40]. Aiming for an effective assessment of a novel therapy for patients with AML, a randomized, double-blind, multicenter, placebo controlled phase III trial (ClinicalTrials.gov, NCT03416179) of glasdegib in combination with intensive chemotherapy or azacitidine in patients with untreated AML is ongoing.

### Table 3: Treatment-emergent all-causality adverse events occurring in ≥20% of patients in any treatment

| MedDRA preferred term | Glasdegib 100 mg + LDAC, N = 84 | LDAC, N = 41 |
|-----------------------|----------------------------------|-------------|
|                       | Grade 1–2  | Grade 3–4  | Grade 5  | Total  | Grade 1–2  | Grade 3–4  | Grade 5  | Total  |
| Any AEs               | 6 (7.1)    | 54 (64.3)  | 24 (28.6)| 84 (100.0)| 1 (2.4)    | 23 (56.1)  | 17 (41.5)| 41 (100.0)|
| Anemia                | 3 (3.6)    | 35 (41.7)  | 0 (0)   | 38 (45.2)| 2 (4.9)    | 15 (36.6)  | 0 (0)   | 17 (41.5)|
| Febrile neutropenia   | 0 (0)      | 30 (35.7)  | 0 (0)   | 30 (35.7)| 0 (0)      | 10 (24.4)  | 0 (0)   | 10 (24.4)|
| Nausea                | 28 (33.3)  | 2 (2.4)    | 0 (0)   | 30 (35.7)| 4 (9.8)    | 1 (2.4)    | 0 (0)   | 5 (12.2)|
| Decreased appetite    | 25 (29.8)  | 3 (3.6)    | 0 (0)   | 28 (33.3)| 3 (7.3)    | 2 (4.9)    | 0 (0)   | 5 (12.2)|
| Fatigue               | 14 (16.7)  | 12 (14.3)  | 0 (0)   | 26 (31.0)| 6 (14.6)   | 2 (4.9)    | 0 (0)   | 8 (19.5)|
| Thrombocytopenia      | 0 (0)      | 26 (31.0)  | 0 (0)   | 26 (31.0)| 1 (2.4)    | 10 (24.4)  | 0 (0)   | 11 (26.8)|
| Pneumonia             | 4 (4.8)    | 14 (16.7)  | 6 (7.1) | 24 (28.6)| 1 (2.4)    | 6 (14.6)   | 3 (7.3) | 10 (24.4)|
| Diarrhea              | 19 (22.6)  | 4 (4.8)    | 0 (0)   | 23 (27.4)| 8 (19.5)   | 1 (2.4)    | 0 (0)   | 9 (22.0)|
| Pyrexia               | 21 (25.0)  | 2 (2.4)    | 0 (0)   | 23 (27.4)| 7 (17.1)   | 2 (4.9)    | 0 (0)   | 9 (22.0)|
| Edema peripheral      | 22 (26.2)  | 0 (0)      | 0 (0)   | 22 (26.2)| 6 (14.6)   | 1 (2.4)    | 0 (0)   | 7 (17.1)|
| Constipation          | 20 (23.8)  | 1 (1.2)    | 0 (0)   | 21 (25.0)| 6 (14.6)   | 0 (0)      | 0 (0)   | 6 (14.6)|
| Dysgeusia             | 21 (25.0)  | 0 (0)      | 0 (0)   | 21 (25.0)| 2 (4.9)    | 0 (0)      | 0 (0)   | 1 (2.4)|
| Dyspnea               | 15 (17.9)  | 6 (7.1)    | 0 (0)   | 21 (25.0)| 9 (22.0)   | 2 (4.9)    | 0 (0)   | 11 (26.8)|
| Muscle spasms         | 15 (17.9)  | 4 (4.8)    | 0 (0)   | 19 (22.6)| 2 (4.9)    | 0 (0)      | 0 (0)   | 2 (4.9)|
| Cough                 | 18 (21.4)  | 0 (0)      | 0 (0)   | 18 (21.4)| 6 (14.6)   | 1 (2.4)    | 0 (0)   | 7 (17.1)|
| Dizziness             | 17 (20.2)  | 1 (1.2)    | 0 (0)   | 18 (21.4)| 4 (9.8)    | 0 (0)      | 0 (0)   | 4 (9.8)|
| Vomiting              | 16 (19.0)  | 2 (2.4)    | 0 (0)   | 18 (21.4)| 3 (7.3)    | 1 (2.4)    | 0 (0)   | 4 (9.8)|

**Note:** AEs indicate adverse events, LDAC low-dose cytarabine, MedDRA Medical Dictionary for Regulatory Activities

*MedDRA (version 19.1) coding dictionary applied*
The addition of glasdegib to LDAC resulted in a favorable benefit-to-risk profile given the statistically significant and clinically meaningful improvement in OS compared with the standard therapy of LDAC and generally manageable toxicity. Therefore, the combination of glasdegib plus LDAC may represent a promising treatment strategy for patients with AML or high-risk MDS who are not suitable for intensive chemotherapy.

Acknowledgements This study is sponsored by Pfizer Inc. Upon request and subject to certain criteria, conditions, and exceptions (see https://www.pfizer.com/science/clinical-trials/trial-data-and-results for more information), Pfizer will provide access to individual de-identified participant data from Pfizer-sponsored global interventional clinical studies conducted for medicines, vaccines, and medical devices (1) for indications that have been approved in the US and/or EU or (2) in programs that have been terminated (i.e., development for all indications has been discontinued). Pfizer will also consider requests for the protocol, data dictionary, and statistical analysis plan. Data may be requested from Pfizer trials 24 months after study completion. The de-identified participant data will be made available to researchers whose proposals meet the research criteria and other conditions and for which an exception does not apply, via a secure portal. To gain access, data requestors must enter into a data access agreement with Pfizer. Medical writing support was provided by Vardit Dror, PhD and Shuang Li, PhD of Engage Scientific Solutions and funded by Pfizer.

Funding This study was sponsored by Pfizer Inc.

Compliance with ethical standards

Conflict of interest JEC received research funding and consulting honoraria from Pfizer, Novartis, Astellas, Daiichi, and Celgene. FHI received honoraria from Pfizer. WF participated in advisory boards for Amgen, Pfizer, Novartis, Jazz, and ARCAD/Incyte; has patents and royalties from Amgen; and received support for meeting attendance from Amgen, Gilead, GSO, Teva, and Jazz and research funding from Amgen and Pfizer. BDS served on an advisory board and was a consultant for Celgene, Jazz Pharmaceuticals, Novartis, and Pfizer. TR received research funding from Pfizer. PM served on an advisory board for Genentech, Jazz, Janssen, and Novartis and has received research funding from Pfizer and Celgene. DAP served on an advisory board for Celgene, Jazz, Janssen, and Novartis and has received research funding from Pfizer and Celgene. DAP served on an advisory board for Celgene, Jazz, Janssen, and Novartis and has received research funding from Pfizer and Celgene. DAP served on an advisory board for Celgene, Jazz, Janssen, and Novartis and has received research funding from Pfizer and Celgene. AH, PD, and OO were investigators for this Pfizer-funded study and received study drug donations by Pfizer. MH received research funding and honoraria from Pfizer. WWM, MNS, ADL, MZ, AO, and GC are employees of and own stock in Pfizer Inc.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Klepin HD, Rao AV, Pardee TS. Acute myeloid leukemia and myelodysplastic syndromes in older adults. J Clin Oncol. 2014;32:2541–52.
2. Burnett AK, Milligan D, Prentice AG, Goldstone AH, McMullin MF, Hills RK, et al. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer. 2007;109:1114–24.
3. Burnett AK, Hills RK, Hunter A, Milligan D, Kell J, Wheatley K, et al. The addition of arsenic trioxide to low-dose Ara-C in older patients with AML does not improve outcome. Leukemia. 2011;25:1122–7.
4. Burnett AK, Russell NH, Culligan D, Cavanagh J, Kell J, Wheatley K, et al. The addition of the farnesyl transferase inhibitor, tipifarnib, to low dose cytarabine does not improve outcome for older patients with AML. Br J Haematol. 2012;158:519–22.
5. Kantarjian HM, Thomas XG, Dmoszynska A, Wierzbowska A, Mazur G, Mayer J, et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol. 2012;30:3670–7.
6. Döhner H, Lübbert M, Fiedler W, Fouillard L, Haaland L, Brandwein JM, et al. Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy. Blood. 2014;124:1426–33.
7. Heiblig M, Elhamri M, Tigaud I, Plesa A, Barraco F, Labussiere H, et al. Treatment with low-dose cytarabine in elderly patients (age 70 years or older) with acute myeloid leukemia: a single institution experience. Mediterr J Hematol Infect Dis. 2016;8:e2016009.
8. Ok CY, Singh RR, Vega F. Aberrant activation of the hedgehog signaling pathway in malignant hematological neoplasms. Am J Pathol. 2012;180:2–11.
9. Irvine DA, Copland M. Targeting hedgehog in hematologic malignancy. Blood. 2012;119:2196–204.
10. Heidel FH, Arreba-Tutusaus P, Armstrong SA, Fischer T. Evolutionarily conserved signaling pathways: acting in the shadows of acute myelogenous leukemia’s genetic diversity. Clin Cancer Res. 2015;21:240–8.
11. Wellbrock C, Latuske E, Kohler J, Wagner K, Stamm H, Vettorazzi E, et al. Expression of Hedgehog pathway mediator GLI1 represents a negative prognostic marker in human acute myeloid leukemia and its inhibition exerts antileukemic effects. Clin Cancer Res. 2015;21:2388–98.
12. Queiroz KC, Ruela-de-Sousa RR, Fulher GM, Aberson HL, Ferreira CV, Peppelens Bosch MP, et al. Hedgehog signaling maintains chemoresistance in myeloid leukemic cells. Oncogene. 2010;29:6314–22.
13. Sadarangani A, Pineda G, Lennon KM, Chun HJ, Shih A, Schairer AE, et al. GLI2 inhibition abrogates human leukemia stem cell dormancy. J Transl Med. 2015;13:98.
14. Fukushima N, Minami Y, Kakiuchi S, Kuwatsuka Y, Hayakawa F, Jamieson C, et al. Small-molecule Hedgehog inhibitor attenuates the leukemia-initiation potential of acute myeloid leukemia cells. Cancer Sci. 2016;107:1422–9.
15. Martinek G, Oehler VG, Papayannidis C, Courtney R, Shaik MN, Zhang X, et al. Treatment with PF-04449913, an oral smoothened
antagonist, in patients with myeloid malignancies: a phase 1 safety and pharmacokinetics study. Lancet Haematol. 2015;2:e339–46.
16. Minami Y, Minami H, Miyamoto T, Yoshimoto G, Kobayashi Y, Munakata W, et al. Phase I study of glasdegib (PF-04449913), an oral smoothened inhibitor, in Japanese patients with select hematologic malignancies. Cancer Sci. 2017;108:1628–33.
17. Savona M, Polleyea D, Stock W, Oehler V, Schroeder M, Lancing J, et al. Phase Ib study of Glasdegib, a Hedgehog pathway inhibitor, in combination with standard chemotherapy in patients with AML or high-risk MDS. Clin Cancer Res. 2018;24:2294–303.
18. Cortes JE, Douglas Smith B, Wang ES, Merchant A, Oehler VG, Arellano M, et al. Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: Phase 2 study results. Am J Hematol. 2018;93:1301–10.
19. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Dombret H, Seymour JF, Butrym A, Wierzbowska A, Selleslag D, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114:937–51.
20. Kantarjian H, O’Brien S, Cortes J, Giles F, Faderl S, Jabbour E, et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer. 2006;106:1090–8.
21. Döhner H, Estey E, Amadori S, Albitar M, Appelbaum FR, Buchner T, Burnett AK, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an International Expert Panel, on behalf of the European LeukemiaNet. Blood. 2010;115:453–74.
22. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;90:2079–88.
23. Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, Estey EH, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003;21:4642–9.
24. Mignot M, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006;108:1459–21.
25. Temple R. Hy’s law: predicting serious hepatotoxicity. Pharmacoepidemiol Drug Saf. 2006;15:241–3.
26. Dombret H, Seymour JF, Batyrin A, Wierzbowska A, Selleslag D, Jang JH, et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with ≥30% blasts. Blood. 2015;126:291–9.
27. Dennis M, Hills R, Thomas I, Kallenbach M, Hemmaway C, Greaves P, et al. A randomised evaluation of low-dose Ara-C plus tosedostat versus low dose Ara-C in older patients with acute myeloid leukaemia: results of the LI-I trial. EHA2018 Abstract S117. https://learningcenter.eahweb.org/eha/2018/stockholm/214439/mike.denn. Accessed on 25 Oct 2018.
28. Burnett AK, Hills RK, Hunter AE, Milligan D, Kell WJ, Wheatley K, et al. The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison. Leukemia. 2013;27:75–81.
29. Burnett AK, Russell N, Hills RK, Panoskaltsis N, Khwaja A, Hemmaway C, et al. A randomised comparison of the novel nucleoside analogue capcitabine with low-dose cytarabine in older patients with acute myeloid leukaemia. Leukemia. 2015;29:1312–9.
30. Lindsley RC, Mar BG, Mazzola E, Grauman PV, Shareef S, Allen SL, et al. Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood. 2015;125:1367–76.
31. Sekeres MA, Cortes JE, Wood BL, Grove LE, Sandalich L, Sievers EL, et al. Randomized phase IIb study of low-dose cytarabine and lintuzumab versus low-dose cytarabine and placebo in older adults with untreated acute myeloid leukemia. Haematologica. 2013;98:119–28.